Affordable Access

Access to the full text

HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway

Authors
  • Wang, Xinyu1
  • Shi, Bowen1
  • Zhao, Yue1
  • Lu, Qijue1
  • Fei, Xiang1
  • Lu, Chaojing1
  • Li, Chunguang1
  • Chen, Hezhong1
  • 1 Changhai Hospital, Second Military Medical University, Shanghai, 200433, China , Shanghai (China)
Type
Published Article
Journal
Cancer Cell International
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Sep 12, 2020
Volume
20
Issue
1
Identifiers
DOI: 10.1186/s12935-020-01539-7
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundHexokinase domain component 1 (HKDC1) plays an oncogenic role in certain types of cancer, such as lymphoma, liver cancer, and breast cancer. Previous bioinformatics study revealed that HKDC1 was significantly upregulated in lung adenocarcinoma (LUAD). However, its biological functions and potential mechanism in LUAD have not been studied.MethodsWe performed bioinformatics analysis, quantitative real-time polymerase chain reaction (qRT-PCR), western blotting, immunohistochemistry, and a series of functional assays in vitro and in vivo to investigate the roles of HKDC1 in LUAD.ResultsWe discovered that HKDC1 was highly expressed in LUAD tissues and cell lines, and the positive expression of HKDC1 was correlated with aberrant clinicopathological characteristics in LUAD patients. Furthermore, HKDC1 could serve as a prognostic predictor for LUAD patients. Overexpression of HKDC1 promoted proliferation, migration, invasion, glycolysis, EMT and tumorigenicity, whereas knockdown of HKDC1 produced the opposite functional effects. Mechanistically, HKDC1 could regulate the AMPK/mTOR signaling pathway to perform its biological function.ConclusionsOur findings suggest that HKDC1 plays an oncogenic role in LUAD. Targeting this gene may provide a promising therapeutic target to delay LUAD progression.

Report this publication

Statistics

Seen <100 times